Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and SBRT in Stage III NSCLC
NCT03589547Phase 2Completed
- Sponsor
- Brown University
- Start
- May 2019
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Brown University. Started May 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03589547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589547.